Please login to the form below

Not currently logged in
Email:
Password:
I have forgotten my password

NHS England

This page shows the latest NHS England news and features for those working in and with pharma, biotech and healthcare.

NHS seeks 'solution creators' from within pharma

NHS seeks 'solution creators' from within pharma

The NHS is moving into a new era of relations with the pharmaceutical industry, according to NHS England. ... However, he was clear about what NHS England wanted from the pharmaceutical industry.

Latest news

  • NICE reverses its rejection of Eisai’s Lenvima NICE reverses its rejection of Eisai’s Lenvima

    However, NICE - the body that weighs up medication costs versus disease effectiveness for NHS England - originally rejected Lenvima last year, claiming in draft guidance the drug was not cost-effective. ... that NICE is finally recommending the use of

  • NICE backs Roche’s Gazyvaro after initial rejection NICE backs Roche’s Gazyvaro after initial rejection

    Previously, NICE also cleared Gazyvaro as a routine NHS treatment option for adults with chronic lymphocytic leukaemia (CLL). ... Close collaboration between Roche, NHS England and NICE has resulted in NICE recommending Gazyvaro as a cost effective

  • Roche’s lung drug Esbriet reserved for worse cases, says NICE Roche’s lung drug Esbriet reserved for worse cases, says NICE

    Boehringer Ingelheim’s Ofev subject to same conditions. Roche’s idiopathic pulmonary fibrosis drug Esbriet will be available routinely on the NHS in England and Wales, but only for patients with

  • NICE backs trial of online and mobile depression programme NICE backs trial of online and mobile depression programme

    NICE has issued its first digital psychological therapy briefing and concluded that online and mobile programme Deprexis should be trialed on the NHS. ... Deprexis will now undergo a two-year trial as part of NHS England’s Improving Access to

  • NICE finally starts review of Biogen’s Spinraza for SMA NICE finally starts review of Biogen’s Spinraza for SMA

    In a statement, Biogen points out that “on its own this choice of route could have signalled a setback for access, the openness demonstrated by NICE and NHS England to commence ... development of a Managed Access Agreement straight away has reassured

More from news
Approximately 33 fully matching, plus 380 partially matching documents found.

Latest Intelligence

  • Working with our healthcare system more closely is vital Working with our healthcare system more closely is vital

    Need for a balanced PPRS agreement which works for patients, NHS and industry. ... England. Medicines spend growth within the PPRS stable at 1.1% (fallen 0.4%) while NHS spend growth is higher at 3.3%.

  • Pulling together Pulling together

    Responding to the charge that NICE only exists to present a rationale for the use of resources, he said: “That’s NHS England’s job, it’s not our job at ... Now’s the time. Looking to the future Professor Keith McNeil, NHS chief clinical

  • Effective strategic planning Effective strategic planning

    Another problem, told to PME by Paul Midgley, director of NHS Insight at Wilmington Healthcare, is that pharma typically struggles to match customer needs to its own value proposition. ... Another example is the evolvement of regional health and care

  • Macron, Merkel and May: implications of the 2017 elections for the life science industry Macron, Merkel and May: implications of the 2017 elections for the life science industry

    In April 2017, NICE and NHS England introduced affordability measures to manage the uptake of innovative treatments, including a £20m budget impact threshold for all new medicines. ... The ABPI has pursued legal action, arguing that this contravenes the

  • Tackling the challenge of non-adherence Tackling the challenge of non-adherence

    The figures are striking. In England, the overall NHS drug spend has increased by 8% between 2015 and 2016, reaching £16.8bn. ... As Dimitrios notes: “The NHS is under huge financial pressure and is being challenged to become more efficient.

More from intelligence
Approximately 1 fully matching, plus 28 partially matching documents found.

Latest appointments

More from appointments
Approximately 3 fully matching, plus 13 partially matching documents found.

Latest from PMHub

More from PMHub
Approximately 1 fully matching, plus 1 partially matching documents found.

Featured jobs

Subscribe to our email news alerts

PMHub

Add my company
M&F Health

M&F Health is a full service communications agency, dedicated to the health and wellbeing sector. We are an independent amongst...

Latest intelligence

Why heading online for scientific meetings can yield greater HCP engagement
Modern conferencing methods, with enhanced digital information transfers, offer unique opportunities for greater HCP engagement....
The threat of antimicrobial resistance
Why this issue is such a fundamental challenge...
Meet the CEO behind ReNeuron’s cutting-edge stem cell therapies
Blue Latitude Health speaks to Olav Hellebo, CEO of ReNeuron, to find out about the biotech’s latest innovation in stem cell therapy and to learn his perspective on navigating the...

Quick links

Infographics

Multimedia